When was Multiplier.ai founded?

Multiplier.ai was founded in 2020 and raised its 1st funding round 6 years after it was founded.

Where is Multiplier.ai located?

Multiplier.ai is headquartered in New York City, United States.

Is Multiplier.ai a funded company?

Multiplier.ai is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Aug 21, 2026.

When was the latest funding round of Multiplier.ai?

Multiplier.ai's latest funding was a $***** Seed round on Aug 21, 2026, with participation from 11 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $4.34B in funding in 2026 to date.

Where does Multiplier.ai rank among its competitors?

Multiplier.ai ranks 89th amongst 295 active competitors, of which 89 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Multiplier.ai, which secured $6M in Aug, 2026.

Who are the top competitors of Multiplier.ai?

Multiplier.ai's top competitors include Schrodinger, Relay Therapeutics and XtalPi. Among them, Multiplier.ai secured the most recent funding round in August, 2026.

Multiplier.ai - 2026 Company Profile, Funding & Competitors

Company Details

Provider of an AI-first solutions for healthcare. It is offering an AI platform discovering drugs, pharmaceutical companies leverage technology to enhance the efficiency and effectiveness of their operations.

Key Metrics

Founded Year

2020

Location

New York City, United States

Stage

Seed

Total Funding

$6M in 1 round

Latest Funding Round

Seed, Aug 21, 2026, $*****

Investors

Lux Capital & 11 more

Ranked

89^th among 295 active competitors

Similar Companies

Schrodinger & 300 more

View Multiplier.ai's full profile

Multiplier.ai has raised a total funding of $6M over 1 round. Its latest funding round was a Seed round on Aug 21, 2026 for $*****. 11 investors participated in its latest round. Multiplier.ai has 7 institutional investors and 5 angel investors.

Here is the list of recent funding rounds of Multiplier.ai:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 21, 2026	5129730	Seed	3390709	1303482	7362363	2870872

Access funding benchmarks and valuations. Sign up today!

View details of Multiplier.ai's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Multiplier.ai include Schrodinger, Relay Therapeutics and XtalPi. Here is the list of Top 10 competitors of Multiplier.ai, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	72/100
2nd	Relay Therapeutics 2016, Cambridge (United States), Public	Developer of drug discovery platform and study protein motion	$520M	BVF Partners, SoftBank Vision Fund & 17 others	69/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Orbimed & 25 others	69/100
4th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	69/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	65/100
6th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	64/100
7th	Iambic Therapeutics 2019, San Diego (United States), Public	Provider of AI-driven drug discovery platform for the treatment of cancer	$334M	Abingworth, Exor & 26 others	64/100
8th	Genesis Therapeutics 2019, San Francisco (United States), Series B	Developer of an AI platform for discovering and designing novel drugs	$304M	Andreessen Horowitz, Rock Springs Capital ... & 16 others	64/100
9th	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 48 others	64/100
10th	Aqemia 2019, Paris (France), Series A	Provider of an AI and quantum physics to discover therapeutic molecules	$101M	Cathay Innovation, Elaia & 4 others	63/100
89th	Multiplier.ai 2020, New York City (United States), Seed	Provider of an AI-first solutions for healthcare	$6M	General Advance, Amino Capital & 10 others	33/100